Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG: MIJ821
DRUG: Placebo
DRUG: Ketamine

Sponsor

Novartis Pharmaceuticals